Similar articles

• Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.

  Lewis RL, Canafax DM, Pettit KG, DiCesare J, Kaniecki DJ, Arnold RJ, Roberts MS. Lewis RL, et al. Transplant Proc. 1996 Aug;28(4):2214-7. Transplant Proc. 1996. PMID: 8769203 Clinical Trial. No abstract available.
• Application of cyclosporine in renal transplantation: experience at the University of Padua.

  Furian L, Baldan N, Rigotti P. Furian L, et al. Transplant Proc. 2004 Mar;36(2 Suppl):148S-151S. doi: 10.1016/j.transproceed.2004.01.008. Transplant Proc. 2004. PMID: 15041326
• Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation.

  Abella I. Abella I. Transplant Proc. 1996 Dec;28(6):3131-4. Transplant Proc. 1996. PMID: 8962213 Review. No abstract available.
• Cyclosporine withdrawal improves long-term graft survival in renal transplantation.

  Gallagher M, Jardine M, Perkovic V, Cass A, McDonald S, Petrie J, Eris J. Gallagher M, et al. Transplantation. 2009 Jun 27;87(12):1877-83. doi: 10.1097/TP.0b013e3181a76823. Transplantation. 2009. PMID: 19543068 Clinical Trial.
• Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

  Nashan B. Nashan B. Transplant Rev (Orlando). 2009 Jan;23(1):47-52. doi: 10.1016/j.trre.2008.08.005. Transplant Rev (Orlando). 2009. PMID: 19027616 Review.